Synthesis and biological evaluation of new pyrimidine-4-yl-ethanol derivatives as ROS1 kinase inhibitors
- 18 June 2014
- journal article
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 30 (2) , 290-298
Abstract
As a part of trials to target ROS1 kinase with potential inhibitors, a novel series of pyrimidin-4-yl-ethanol and ethanone derivatives (4a-f, 5a-f, 6a-f and 7a-f) have been designed based on previously discovered lead compounds KIST301072 and KIST301080, and synthesized on 4-5 steps according to compounds. The structures of the newly synthesized compounds have been confirmed on (1)H-NMR, (13)C-NMR and IR. Most of the tested compounds showed ROS1 kinase inhibitory activity in micromolar range.Keywords
This publication has 13 references indexed in Scilit:
- The molecular basis of targeting protein kinases in cancer therapeuticsSeminars in Cancer Biology, 2013
- Kinases as targets in the treatment of solid tumorsCellular Signalling, 2010
- Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issuesEuropean Journal of Pharmacology, 2009
- Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitorBioorganic & Medicinal Chemistry Letters, 2009
- Targeting cancer with small molecule kinase inhibitorsNature Reviews Cancer, 2009
- Tyrosine kinase – Role and significance in CancerInternational Journal of Medical Sciences, 2004
- Protein kinases — the major drug targets of the twenty-first century?Nature Reviews Drug Discovery, 2002
- Oncogenic kinase signallingNature, 2001
- The protein tyrosine kinase family of the human genomeOncogene, 2000
- Signaling by dual specificity kinasesOncogene, 1998